Related Experiment Video
Updated: Feb 27, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT
Carmela De Marco1, Carmelo Laudanna1, Nicola Rinaldo2
1Dipartimento di Medicina Sperimentale e Clinica, Università "Magna Graecia", Catanzaro, Italia.
Abstract:
Hyperactivation of the phosphatydil-inositol-3' phosphate kinase (PI3K)/AKT pathway is observed in most NSCLCs, promoting proliferation, migration, invasion and resistance to therapy. AKT can be activated through several mechanisms that include loss of the negative regulator PTEN, activating mutations of the catalytic subunit of PI3K (PIK3CA) and/or mutations of AKT1 itself. However, number and identity of downstream targets of activated PI3K/AKT pathway are poorly defined. To identify the genes that are targets of constitutive PI3K/AKT signalling in lung cancer cells, we performed a comparative transcriptomic analysis of human lung epithelial cells (BEAS-2B) expressing active mutant AKT1 (AKT1-E17K), active mutant PIK3CA (PIK3CA-E545K) or that are silenced for PTEN. We found that, altogether, aberrant PI3K/AKT signalling in lung epithelial cells regulated the expression of 1,960/20,436 genes (9%), though only 30 differentially expressed genes (DEGs) (15 up-regulated, 12 down-regulated and 3 discordant) out of 20,436 that were common among BEAS-AKT1-E17K, BEAS-PIK3CA-E545K and BEAS-shPTEN cells (0.1%). Conversely, DEGs specific for mutant AKT1 were 133 (85 up-regulated; 48 down-regulated), DEGs specific for mutant PIK3CA were 502 (280 up-regulated; 222 down-regulated) and DEGs specific for PTEN loss were 1549 (799 up-regulated, 750 down-regulated). The results obtained from array analysis were confirmed by quantitative RT-PCR on selected up- and down-regulated genes (n = 10). Treatment of BEAS-C cells and the corresponding derivatives with pharmacological inhibitors of AKT (MK2206) or PI3K (LY294002) further validated the significance of our findings. Moreover, mRNA expression of selected DEGs (SGK1, IGFBP3, PEG10, GDF15, PTGES, S100P, respectively) correlated with the activation status of the PI3K/AKT pathway assessed by S473 phosphorylation in NSCLC cell lines (n = 6). Finally, we made use of Ingenuity Pathway Analysis (IPA) to investigate the relevant BioFunctions enriched by the costitutive activation of AKT1-, PI3K- or PTEN-dependent signalling in lung epithelial cells. Expectedly, the analysis of the DEGs common to all three alterations highlighted a group of BioFunctions that included Cell Proliferation of tumor cell lines (14 DEGs), Invasion of cells (10 DEGs) and Migration of tumour cell lines (10 DEGs), with a common core of 5 genes (ATF3, CDKN1A, GDF15, HBEGF and LCN2) that likely represent downstream effectors of the pro-oncogenic activities of PI3K/AKT signalling. Conversely, IPA analysis of exclusive DEGs led to the identification of different downstream effectors that are modulated by mutant AKT1 (TGFBR2, CTSZ, EMP1), mutant PIK3CA (CCND2, CDK2, IGFBP2, TRIB1) and PTEN loss (ASNS, FHL2). These findings not only shed light on the molecular mechanisms that are activated by aberrant signalling through the PI3K/AKT pathway in lung epithelial cells, but also contribute to the identification of previously unrecognised molecules whose regulation takes part in the development of lung cancer.
Insights
This study identifies key genes regulated by the PI3K/AKT pathway in lung cancer, revealing common and specific downstream effectors. These findings offer new insights into lung cancer development and potential therapeutic targets.
Area of Science:
- Molecular Biology
- Oncology
- Genomics
Background:
- The PI3K/AKT pathway is frequently hyperactivated in non-small cell lung cancer (NSCLC), driving tumor progression and therapy resistance.
- Mechanisms of PI3K/AKT activation include PTEN loss and mutations in PIK3CA or AKT1.
- The precise downstream targets of this aberrant signaling in lung cancer remain incompletely understood.
Purpose of the Study:
- To identify genes regulated by constitutive PI3K/AKT signaling in lung epithelial cells.
- To differentiate downstream targets common to various PI3K/AKT activation mechanisms (mutant AKT1, mutant PIK3CA, PTEN loss).
- To explore the functional implications of these differentially expressed genes in lung cancer.
Main Methods:
- Comparative transcriptomic analysis of human lung epithelial cells (BEAS-2B) with specific genetic alterations (AKT1-E17K, PIK3CA-E545K, shPTEN).
- Validation of array data using quantitative RT-PCR.
- Pharmacological inhibition of AKT and PI3K pathways.
- Correlation analysis of mRNA expression with pathway activation markers (S473 phosphorylation).
- Pathway analysis using Ingenuity Pathway Analysis (IPA) to identify enriched biological functions.
Main Results:
- Aberrant PI3K/AKT signaling regulated 9% of genes, with only 0.1% common across all tested alterations.
- Specific DEGs were identified for each alteration: 133 for AKT1, 502 for PIK3CA, and 1549 for PTEN loss.
- Common DEGs enriched for functions including cell proliferation, invasion, and migration, with a core of 5 genes (ATF3, CDKN1A, GDF15, HBEGF, LCN2).
- Exclusive DEGs identified distinct downstream effectors for each specific alteration.
Conclusions:
- Constitutive PI3K/AKT signaling in lung epithelial cells activates a complex network of downstream genes.
- A core set of genes (ATF3, CDKN1A, GDF15, HBEGF, LCN2) are key mediators of PI3K/AKT's pro-oncogenic activities.
- Identification of specific and common downstream effectors provides novel insights into lung cancer pathogenesis and potential therapeutic targets.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
lncRNA - Long Non-coding RNAs
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...